Covidien rolls out advanced bedside monitor; Cardiologist testifies in suit alleging excessive stent use;

@FierceMedDev: Biotronik unveils next-gen MRI-safe ICDs. ICYMI yesterday | Follow @FierceMedDev

@MarkHFierce: Quest Diagnostics warns that its Q3 numbers won't be meeting expectations. Blame reimbursement pressures, etc. More | Follow @MarkHFierce

@MichaelGFierce: Check out this week's FierceDrugDelivery newsletter! RNAi roundup & stem cell drug delivery action. Report | Follow @MichaelGFierce

> Covidien ($COV) is rolling out a new bedside monitor that it said will help clinicians spot and tackle serious health threats sooner. Item

> Baltimore cardiologist Dr. Mark Midei took the stand in a civil suit accusing him of performing unnecessary stent procedures. Story

> Imris ($IMRS) and Siemens Healthcare will collaborate to market intraoperative CT scanners. Item

> Ireland's Crospon nailed down FDA clearance for its new EsoFLIP balloon dilation catheter designed for procedures in the esophagus and colon. Item

> The disposable medical devices sensors market will come close to doubling from 2013 to 2018, hitting a value of more than $6.2 billion at the end of that period,  a new industry report concluded. Item

> Particle Sciences in Pennsylvania said it has successfully completed the clinical trial manufacturing of vaginal ring devices that deliver a drug designed to help prevent HIV. Item

Biotech News

@FierceBiotech: Still popular: 10 top drugs in biopharma's late-stage pipeline. Feature | Follow @FierceBiotech

@JohnCFierce: Osiris exits stem cell business, sells unit to Mesoblast in $100M deal. News | Follow @JohnCFierce

@DamianFierce: In case you missed it, some thoughts on why med tech companies aren't riding the biotech IPO wave. Editor's Corner | Follow @DamianFierce

@EmilyMFierce: Compound halts neurodegeneration in mice. Story from FierceBiotech Research | Follow @EmilyMFierce

> Celladon, Xencor bid for $155M in red-hot IPO market. Story

> Researchers hit Alzheimer's 'turning point' with new target. Article

> MacroGenics shares soar on glittering $80M IPO debut. Report

Pharma News

@FiercePharma: Top 10 Drugmakers in Emerging Markets--our latest special report. Feature | Follow @FiercePharma

@EricPFierce:  spent €39B on emerging markets deals over 4 years. It has 40 manufacturing sites in these countries. More | Follow @EricPFierce

@CarlyHFierce: Vivus and Auxilium sign marketing deal for ED drug Stendra in the U.S. and Canada. Article | Release | Follow @CarlyHFierce

> Fresenius punished distributor for selling its drug for executions. Report

> J&J, AstraZeneca take Zytiga to Japan. Article

> FDA signoff on Ranbaxy NJ plant may provide drugmaker relief. Story